NASDAQ:ASND Ascendis Pharma A/S Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $152.26 +0.32 (+0.21 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$148.25Now: $152.26▼$154.0550-Day Range$137.82MA: $143.82▼$154.0352-Week Range$90.06Now: $152.26▼$158.93Volume277,442 shsAverage Volume210,331 shsMarket Capitalization$8.05 billionP/E RatioN/ADividend YieldN/ABeta0.87 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $172.45, Ascendis Pharma A/S has a forecasted upside of 13.3% from its current price of $152.26.Amount of Analyst CoverageAscendis Pharma A/S has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAscendis Pharma A/S has received 329 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAscendis Pharma A/S has received 300 “underperform” votes. (Add your “underperform” vote.)Community SentimentAscendis Pharma A/S has received 52.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote “Outperform” if you believe ASND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.39% of the stock of Ascendis Pharma A/S is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($7.35) to ($7.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -24.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -24.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAscendis Pharma A/S has a P/B Ratio of 9.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASND Previous Symbol CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone45-7022-2244Debt Debt-to-Equity Ratio0.06 Current Ratio9.04 Quick Ratio9.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.98 million Price / Sales537.13 Cash FlowN/A Price / Cash FlowN/A Book Value$15.87 per share Price / Book9.59Profitability EPS (Most Recent Fiscal Year)($5.25) Net Income$-244,180,000.00 Net Margins-3,130.03% Return on Equity-45.97% Return on Assets-40.48%Miscellaneous Employees216 Outstanding Shares52,845,000Market Cap$8.05 billion Next Earnings Date11/16/2020 (Estimated) OptionableOptionable $152.26 +0.32 (+0.21 %) (As of 09/29/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ASND News and Ratings via Email Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions How has Ascendis Pharma A/S's stock been impacted by Coronavirus? Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASND stock has increased by 28.5% and is now trading at $152.26. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Ascendis Pharma A/S? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ascendis Pharma A/S. When is Ascendis Pharma A/S's next earnings date? Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Monday, November 16th 2020. View our earnings forecast for Ascendis Pharma A/S. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Thursday, August, 27th. The biotechnology company reported ($1.97) EPS for the quarter, missing the Zacks' consensus estimate of ($1.66) by $0.31. The biotechnology company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $2.47 million. Ascendis Pharma A/S had a negative net margin of 3,130.03% and a negative return on equity of 45.97%. View Ascendis Pharma A/S's earnings history. What price target have analysts set for ASND? 11 analysts have issued 12-month price objectives for Ascendis Pharma A/S's shares. Their forecasts range from $145.00 to $208.00. On average, they expect Ascendis Pharma A/S's stock price to reach $172.45 in the next year. This suggests a possible upside of 13.3% from the stock's current price. View analysts' price targets for Ascendis Pharma A/S. Who are some of Ascendis Pharma A/S's key competitors? Some companies that are related to Ascendis Pharma A/S include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Beigene (BGNE), Alexion Pharmaceuticals (ALXN), Genmab A/S (GMAB), Shiseido (SSDOY), Genmab A/S (GNMSF), UCB (UCBJF), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Royalty Pharma (RPRX), Catalent (CTLT) and BioMarin Pharmaceutical (BMRN). View all competitors. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH) and NVIDIA (NVDA). Who are Ascendis Pharma A/S's key executives? Ascendis Pharma A/S's management team includes the following people: Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58) When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." How do I buy shares of Ascendis Pharma A/S? Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $152.26. How big of a company is Ascendis Pharma A/S? Ascendis Pharma A/S has a market capitalization of $8.05 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe. What is Ascendis Pharma A/S's official website? The official website for Ascendis Pharma A/S is www.ascendispharma.com. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
